{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T06:33:18Z","timestamp":1773729198302,"version":"3.50.1"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Ministry of Science & Technology, Department of Science & Technology","award":["SR\/FST\/LS- I\/2018\/131"],"award-info":[{"award-number":["SR\/FST\/LS- I\/2018\/131"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s11095-022-03323-w","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:03:02Z","timestamp":1656633782000},"page":"2119-2134","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens"],"prefix":"10.1007","volume":"39","author":[{"given":"Shobha","family":"Upreti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0154-2421","authenticated-orcid":false,"given":"Mukesh","family":"Samant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,1]]},"reference":[{"key":"3323_CR1","doi-asserted-by":"publisher","first-page":"17718","DOI":"10.1038\/s41598-020-73955-8","volume":"10","author":"B Liu","year":"2020","unstructured":"Liu B, Han J, Cheng X, Yu L, Zhang L, Wang W, et al. Reduced numbers of T cells and B cells correlates with persistent SARS-CoV-2 presence in non-severe COVID-19 patients. Sci Rep. 2020;10:17718.","journal-title":"Sci Rep"},{"key":"3323_CR2","doi-asserted-by":"crossref","unstructured":"Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. Gallagher T, editor. J Virol. 2020:94.","DOI":"10.1128\/JVI.00127-20"},{"key":"3323_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12929-020-00703-5","volume":"28","author":"IP Trougakos","year":"2021","unstructured":"Trougakos IP, Stamatelopoulos K, Terpos E, Tsitsilonis OE, Aivalioti E, Paraskevis D, et al. Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. J Biomed Sci. 2021;28:9.","journal-title":"J Biomed Sci"},{"key":"3323_CR4","doi-asserted-by":"publisher","first-page":"101422","DOI":"10.1016\/j.smim.2020.101422","volume":"50","author":"L Grigoryan","year":"2020","unstructured":"Grigoryan L, Pulendran B. The immunology of SARS-CoV-2 infections and vaccines. Semin Immunol. 2020;50:101422.","journal-title":"Semin Immunol"},{"key":"3323_CR5","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1056\/NEJMoa066092","volume":"357","author":"IJ Amanna","year":"2007","unstructured":"Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med. 2007;357:1903\u201315.","journal-title":"N Engl J Med"},{"key":"3323_CR6","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.15585\/mmwr.mm7032e1","volume":"70","author":"AM Cavanaugh","year":"2021","unstructured":"Cavanaugh AM, Spicer KB, Thoroughman D, Glick C, Winter K. Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination \u2014 Kentucky, may\u2013June 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1081\u20133.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"3323_CR7","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1038\/s41598-022-05325-5","volume":"12","author":"S Rahman","year":"2022","unstructured":"Rahman S, Rahman MM, Miah M, Begum MN, Sarmin M, Mahfuz M, et al. COVID-19 reinfections among naturally infected and vaccinated individuals. Sci Rep. 2022;12:1438.","journal-title":"Sci Rep"},{"key":"3323_CR8","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/apa.15673","volume":"110","author":"JF Ludvigsson","year":"2021","unstructured":"Ludvigsson JF. Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19. Acta Paediatr. 2021;110:914\u201321.","journal-title":"Acta Paediatr"},{"key":"3323_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41591-020-01202-8","volume":"27","author":"P Brodin","year":"2021","unstructured":"Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med. 2021;27:28\u201333.","journal-title":"Nat Med"},{"key":"3323_CR10","doi-asserted-by":"crossref","unstructured":"Belot A, Antona D, Renolleau S, Javouhey E, Hentgen V, Angoulvant F, et al. SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020. Euro surveillance\u00a0: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2020;25.","DOI":"10.2807\/1560-7917.ES.2020.25.22.2001010"},{"key":"3323_CR11","doi-asserted-by":"crossref","unstructured":"Toubiana J, Poirault C, Corsia A, Bajolle F, Fourgeaud J, Angoulvant F, et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ . 2020;369:m2094.","DOI":"10.1136\/bmj.m2094"},{"key":"3323_CR12","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.15585\/mmwr.mm6940e1","volume":"69","author":"SB Morris","year":"2020","unstructured":"Morris SB, Schwartz NG, Patel P, Abbo L, Beauchamps L, Balan S, et al. Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection - United Kingdom and United States, march-august 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1450\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"3323_CR13","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.3389\/fphys.2020.571416","volume":"11","author":"V Bajaj","year":"2021","unstructured":"Bajaj V, Gadi N, Spihlman AP, Wu SC, Choi CH, Moulton VR. Aging, immunity, and COVID-19: how age influences the host immune response to coronavirus infections? Front Physiol. 2021;11:1793.","journal-title":"Front Physiol"},{"key":"3323_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271\u2013280.e8.","journal-title":"Cell."},{"key":"3323_CR15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000513198","volume":"27","author":"KP Mishra","year":"2020","unstructured":"Mishra KP, Singh AK, Singh SB. Hyperinflammation and immune response generation in COVID-19. Neuroimmunomodulation. 2020;27:80\u20136.","journal-title":"Neuroimmunomodulation"},{"key":"3323_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/diseases4030026","volume":"4","author":"YX Lim","year":"2016","unstructured":"Lim YX, Ng YL, Tam JP, Liu DX. Human coronaviruses: a review of virus-host interactions. Diseases. 2016;4:26.","journal-title":"Diseases"},{"key":"3323_CR17","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.cell.2020.02.041","volume":"180","author":"KA Fitzgerald","year":"2020","unstructured":"Fitzgerald KA, Kagan JC. Toll-like receptors and the control of immunity. Cell. 2020;180:1044\u201366.","journal-title":"Cell"},{"key":"3323_CR18","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.virol.2015.08.010","volume":"485","author":"JL Nieto-Torres","year":"2015","unstructured":"Nieto-Torres JL, Verdi\u00e1-B\u00e1guena C, Jimenez-Guarde\u00f1o JM, Regla-Nava JA, Casta\u00f1o-Rodriguez C, Fernandez-Delgado R, et al. Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome. Virology. 2015;485:330\u20139.","journal-title":"Virology"},{"key":"3323_CR19","unstructured":"Rodrigues TS, de S\u00e1 KSG, Ishimoto AY, Becerra A, Oliveira S, Almeida L, et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J Exp Med. 2021;218."},{"key":"3323_CR20","unstructured":"Lokugamage KG, Hage A, Schindewolf C, Rajsbaum R, Menachery VD. SARS-CoV-2 is sensitive to type I interferon pretreatment. bioRxiv. 2020."},{"key":"3323_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104811","volume":"179","author":"E Mantlo","year":"2020","unstructured":"Mantlo E, Bukreyeva N, Maruyama J, Paessler S, Huang C. Antiviral activities of type I interferons to SARS-CoV-2 infection. Antivir Res. 2020;179:104811.","journal-title":"Antivir Res"},{"key":"3323_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.2041-1014.2009.00562.x","volume":"25","author":"G Hajishengallis","year":"2010","unstructured":"Hajishengallis G. Too old to fight? Aging and its toll on innate immunity. Mol Oral Microbiol. 2010;25:25\u201337.","journal-title":"Mol Oral Microbiol"},{"key":"3323_CR23","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","volume":"20","author":"MZ Tay","year":"2020","unstructured":"Tay MZ, Poh CM, R\u00e9nia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363\u201374.","journal-title":"Nat Rev Immunol"},{"key":"3323_CR24","doi-asserted-by":"publisher","first-page":"m1966","DOI":"10.1136\/bmj.m1966","volume":"369","author":"CM Petrilli","year":"2020","unstructured":"Petrilli CM, Jones SA, Yang J, Rajagopalan H, O\u2019Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in new York City: prospective cohort study. BMJ. 2020;369:m1966.","journal-title":"BMJ."},{"key":"3323_CR25","doi-asserted-by":"crossref","unstructured":"Song C-Y, Xu J, He J-Q, Lu Y-Q. COVID-19 early warning score: a multi-parameter screening tool to identify highly suspected patients. medRxiv. 2020;2020.03.05.20031906.","DOI":"10.1101\/2020.03.05.20031906"},{"key":"3323_CR26","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1093\/infdis\/jiaa150","volume":"221","author":"F Wang","year":"2020","unstructured":"Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis. 2020;221:1762\u20139.","journal-title":"J Infect Dis"},{"key":"3323_CR27","doi-asserted-by":"crossref","unstructured":"Yu L, Tong Y, Shen G, Fu A, Lai Y, Zhou X, et al. Immunodepletion with Hypoxemia: A Potential High Risk Subtype of Coronavirus Disease 2019. medRxiv. 2020;2020.03.03.20030650.","DOI":"10.1101\/2020.03.03.20030650"},{"key":"3323_CR28","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1093\/cid\/ciaa410","volume":"71","author":"H Chu","year":"2020","unstructured":"Chu H, Chan JF-W, Wang Y, Yuen TT-T, Chai Y, Hou Y, et al. Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19. Clin Infect Dis. 2020;71:1400\u20139.","journal-title":"Clin Infect Dis"},{"key":"3323_CR29","doi-asserted-by":"crossref","unstructured":"Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, et al. The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing. medRxiv. 2020;2020.02.23.20026690.","DOI":"10.1101\/2020.02.23.20026690"},{"key":"3323_CR30","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41591-020-0944-y","volume":"26","author":"AJ Wilk","year":"2020","unstructured":"Wilk AJ, Rustagi A, Zhao NQ, Roque J, Mart\u00ednez-Col\u00f3n GJ, McKechnie JL, et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med. 2020;26:1070\u20136.","journal-title":"Nat Med"},{"key":"3323_CR31","volume-title":"Kuby immunology","author":"J Kuby","year":"2013","unstructured":"Kuby J. Kuby immunology. New York: W.H.Freeman; 2013."},{"key":"3323_CR32","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","volume":"26","author":"Q-X Long","year":"2020","unstructured":"Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26:845\u20138.","journal-title":"Nat Med"},{"key":"3323_CR33","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.cca.2020.04.026","volume":"507","author":"A Padoan","year":"2020","unstructured":"Padoan A, Sciacovelli L, Basso D, Negrini D, Zuin S, Cosma C, et al. IgA-ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: a longitudinal study. Clin Chim Acta. 2020;507:164\u20136.","journal-title":"Clin Chim Acta"},{"key":"3323_CR34","doi-asserted-by":"publisher","first-page":"139","DOI":"10.12688\/wellcomeopenres.15927.1","volume":"5","author":"ER Adams","year":"2020","unstructured":"Adams ER, Ainsworth M, Anand R, Andersson MI, Auckland K, Baillie JK, et al. Antibody testing for COVID-19: a report from the national COVID scientific advisory panel. Wellcome Open Res. 2020;5:139.","journal-title":"Wellcome Open Res"},{"key":"3323_CR35","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1056\/NEJMc2025179","volume":"383","author":"FJ Ibarrondo","year":"2020","unstructured":"Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med. 2020;383:1085\u20137.","journal-title":"N Engl J Med"},{"key":"3323_CR36","doi-asserted-by":"crossref","unstructured":"R\u00f6ltgen K, Wirz OF, Stevens BA, Powell AE, Hogan CA, Najeeb J, et al. SARS-CoV-2 antibody responses correlate with resolution of RNAemia but are short-lived in patients with mild illness. medRxiv. 2020.","DOI":"10.1101\/2020.08.15.20175794"},{"key":"3323_CR37","doi-asserted-by":"crossref","unstructured":"Liu T, Wu S, Tao H, Zeng G, Zhou F, Guo F, et al. Prevalence of IgG antibodies to SARS-CoV-2 in Wuhan \u2013 implications for the ability to produce long-lasting protective antibodies against SARS-CoV-2. medRxiv. 2020;2020.06.13.20130252-2020.06.13.20130252.","DOI":"10.1101\/2020.06.13.20130252"},{"key":"3323_CR38","unstructured":"Tan W, Lu Y, Zhang J, Wang J, Dan Y, Tan Z, et al. Viral Kinetics and Antibody Responses in Patients with COVID-19. medRxiv. 2020;2020.03.24.20042382-2020.03.24.20042382."},{"key":"3323_CR39","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","volume":"26","author":"Q-X Long","year":"2020","unstructured":"Long Q-X, Tang X-J, Shi Q-L, Li Q, Deng H-J, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26:1200\u20134.","journal-title":"Nat Med"},{"key":"3323_CR40","doi-asserted-by":"crossref","unstructured":"Nie S, Zhao X, Zhao K, Zhang Z, Zhang Z, Zhang Z. Metabolic disturbances and inflammatory dysfunction predict severity of coronavirus disease 2019 (COVID-19): a retrospective study. medRxiv . 2020;2020.03.24.20042283.","DOI":"10.1101\/2020.03.24.20042283"},{"key":"3323_CR41","doi-asserted-by":"crossref","unstructured":"Wenjun W, Xiaoqing L, Sipei W, Puyi L, Liyan H, Yimin L, et al. The definition and risks of Cytokine Release Syndrome-Like in 11 COVID-19-Infected Pneumonia critically ill patients: Disease Characteristics and Retrospective Analysis. medRxiv. 2020;2020.02.26.20026989.","DOI":"10.1101\/2020.02.26.20026989"},{"key":"3323_CR42","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41423-020-0401-3","volume":"17","author":"H-Y Zheng","year":"2020","unstructured":"Zheng H-Y, Zhang M, Yang C-X, Zhang N, Wang X-C, Yang X-P, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020;17:541\u20133.","journal-title":"Cell Mol Immunol."},{"key":"3323_CR43","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41591-020-0819-2","volume":"26","author":"I Thevarajan","year":"2020","unstructured":"Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, van de Sandt CE, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med. 2020;26:453\u20135.","journal-title":"Nat Med"},{"key":"3323_CR44","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41423-020-0402-2","volume":"17","author":"M Zheng","year":"2020","unstructured":"Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17:533\u20135.","journal-title":"Cell Mol Immunol"},{"key":"3323_CR45","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cell.2020.11.029","volume":"184","author":"LB Rodda","year":"2021","unstructured":"Rodda LB, Netland J, Shehata L, Pruner KB, Morawski PA, Thouvenel CD, et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. Cell. 2021;184:169\u2013183.e17.","journal-title":"Cell"},{"key":"3323_CR46","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1126\/science.272.5258.54","volume":"272","author":"R Ahmed","year":"1996","unstructured":"Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science. 1996;272:54\u201360.","journal-title":"Science"},{"key":"3323_CR47","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.immuni.2010.12.012","volume":"34","author":"R Morita","year":"2011","unstructured":"Morita R, Schmitt N, Bentebibel S-E, Ranganathan R, Bourdery L, Zurawski G, et al. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity. 2011;34:108\u201321.","journal-title":"Immunity"},{"key":"3323_CR48","doi-asserted-by":"crossref","unstructured":"Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients. medRxiv. 2020;2020.08.01.20166553.","DOI":"10.1101\/2020.08.01.20166553"},{"key":"3323_CR49","doi-asserted-by":"crossref","unstructured":"Perreault J, Tremblay T, Fournier M-J, Drouin M, Beaudoin-Bussi\u00e8res G, Pr\u00e9vost J, et al. Longitudinal analysis of the humoral response to SARS-CoV-2 spike RBD in convalescent plasma donors. bioRxiv. 2020;2020.07.16.206847.","DOI":"10.1101\/2020.07.16.206847"},{"issue":"370","key":"3323_CR50","first-page":"1227","volume":"2020","author":"A Wajnberg","year":"1979","unstructured":"Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 1979;2020(370):1227\u201330.","journal-title":"Science"},{"key":"3323_CR51","doi-asserted-by":"crossref","unstructured":"Cromer D, Juno JA, Khoury D, Reynaldi A, Wheatley AK, Kent SJ, et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat Rev Immunol 2021 21:6. 2021;21:395\u2013404.","DOI":"10.1038\/s41577-021-00550-x"},{"key":"3323_CR52","doi-asserted-by":"crossref","unstructured":"R\u00f6ltgen K, Powell AE, Wirz OF, Stevens BA, Hogan CA, Najeeb J, et al. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol. 2020;5.","DOI":"10.1126\/sciimmunol.abe0240"},{"key":"3323_CR53","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/infdis\/jiaa618","volume":"223","author":"KHD Crawford","year":"2021","unstructured":"Crawford KHD, Dingens AS, Eguia R, Wolf CR, Wilcox N, Logue JK, et al. Dynamics of neutralizing antibody titers in the months after severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis. 2021;223:197\u2013205.","journal-title":"J Infect Dis"},{"key":"3323_CR54","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1038\/s41467-021-22034-1","volume":"12","author":"J Wu","year":"2021","unstructured":"Wu J, Liang B, Chen C, Wang H, Fang Y, Shen S, et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. Nat Commun. 2021;12:1813.","journal-title":"Nat Commun"},{"key":"3323_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/mBio.02590-20","volume":"11","author":"G Beaudoin-Bussi\u00e8res","year":"2020","unstructured":"Beaudoin-Bussi\u00e8res G, Laumaea A, Anand SP, Pr\u00e9vost J, Gasser R, Goyette G, et al. Decline of humoral responses against SARS-CoV-2 spike in convalescent individuals. mBio. 2020;11:1\u20137.","journal-title":"mBio."},{"key":"3323_CR56","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/s41467-021-21444-5","volume":"12","author":"AK Wheatley","year":"2021","unstructured":"Wheatley AK, Juno JA, Wang JJ, Selva KJ, Reynaldi A, Tan H-X, et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat Commun. 2021;12:1162.","journal-title":"Nat Commun"},{"key":"3323_CR57","doi-asserted-by":"crossref","unstructured":"Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371.","DOI":"10.1126\/science.abf4063"},{"key":"3323_CR58","doi-asserted-by":"publisher","first-page":"e2006601","DOI":"10.1371\/journal.pbio.2006601","volume":"16","author":"A Antia","year":"2018","unstructured":"Antia A, Ahmed H, Handel A, Carlson NE, Amanna IJ, Antia R, et al. Heterogeneity and longevity of antibody memory to viruses and vaccines. PLoS Biol. 2018;16:e2006601.","journal-title":"PLoS Biol"},{"key":"3323_CR59","doi-asserted-by":"crossref","unstructured":"Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021 27:7. 2021;27:1205\u201311.","DOI":"10.1038\/s41591-021-01377-8"},{"key":"3323_CR60","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","volume":"591","author":"C Gaebler","year":"2021","unstructured":"Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591:639\u201344.","journal-title":"Nature."},{"key":"3323_CR61","doi-asserted-by":"crossref","unstructured":"Hartley GE, Edwards ESJ, Aui PM, Varese N, Stojanovic S, McMahon J, et al. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Sci Immunol. 2020;5.","DOI":"10.1126\/sciimmunol.abf8891"},{"key":"3323_CR62","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","volume":"183","author":"CR Moderbacher","year":"2020","unstructured":"Moderbacher CR, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183:996\u20131012.e19.","journal-title":"Cell."},{"key":"3323_CR63","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1038\/s41591-020-0995-0","volume":"26","author":"JA Juno","year":"2020","unstructured":"Juno JA, Tan H-X, Lee WS, Reynaldi A, Kelly HG, Wragg K, et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat Med. 2020;26:1428\u201334.","journal-title":"Nat Med"},{"key":"3323_CR64","first-page":"423","volume":"386","author":"MM Hufford","year":"2015","unstructured":"Hufford MM, Kim TS, Sun J, Braciale TJ. The effector T cell response to influenza infection. Curr Top Microbiol Immunol. 2015;386:423\u201355.","journal-title":"Curr Top Microbiol Immunol"},{"key":"3323_CR65","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.cmi.2021.10.005","volume":"28","author":"T Fiolet","year":"2022","unstructured":"Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2022;28:202\u201321.","journal-title":"Clin Microbiol Infect"},{"key":"3323_CR66","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41541-021-00292-w","volume":"6","author":"NC Kyriakidis","year":"2021","unstructured":"Kyriakidis NC, L\u00f3pez-Cort\u00e9s A, Gonz\u00e1lez EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines. 2021;6:28.","journal-title":"NPJ Vaccines"},{"key":"3323_CR67","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Montero C, Fraile-Mart\u00ednez O, Bravo C, Torres-Carranza D, Sanchez-Trujillo L, G\u00f3mez-Lahoz AM, et al. An updated review of SARS-CoV-2 vaccines and the importance of effective vaccination programs in pandemic times. Vaccines (Basel). 2021;9.","DOI":"10.3390\/vaccines9050433"},{"key":"3323_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/microorganisms9030605","volume":"9","author":"K-Y Loo","year":"2021","unstructured":"Loo K-Y, Letchumanan V, Ser H-L, Teoh SL, Law JW-F, Tan LT-H, et al. COVID-19: insights into potential vaccines. Microorganisms. 2021;9:1\u201319.","journal-title":"Microorganisms."},{"key":"3323_CR69","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","volume":"396","author":"FC Zhu","year":"2020","unstructured":"Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396:479\u201388.","journal-title":"Lancet"},{"key":"3323_CR70","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","volume":"21","author":"S Xia","year":"2021","unstructured":"Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial. Lancet Infect Dis. 2021;21:39\u201351.","journal-title":"Lancet Infect Dis"},{"key":"3323_CR71","doi-asserted-by":"crossref","unstructured":"Lamb YN. BNT162b2 mRNA COVID-19 vaccine: first approval. Drugs . Drugs; 2021;81:495\u2013501.","DOI":"10.1007\/s40265-021-01480-7"},{"key":"3323_CR72","doi-asserted-by":"crossref","unstructured":"Pulendran B, Arunachalam PS. Systems biological assessment of human immunity to BNT162b2 mRNA vaccination. Res Sq. 2021.","DOI":"10.21203\/rs.3.rs-438662\/v1"},{"key":"3323_CR73","doi-asserted-by":"crossref","unstructured":"Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. medRxiv. 2020;2020.12.09.20245175-2020.12.09.20245175.","DOI":"10.1101\/2020.12.09.20245175"},{"key":"3323_CR74","unstructured":"BioNTech. An In Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with a Mutation Associated with Rapid Transmission | pfpfizeruscom. 2021."},{"key":"3323_CR75","doi-asserted-by":"crossref","unstructured":"Xie X, Liu Y, Liu J, Zhang X, Zou J, Fontes-Garfias CR, et al. Neutralization of SARS-CoV-2 spike 69\/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat Med. 2021 27:4. 2021;27:620\u20131.","DOI":"10.1038\/s41591-021-01270-4"},{"key":"3323_CR76","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603\u201315.","journal-title":"N Engl J Med"},{"key":"3323_CR77","doi-asserted-by":"crossref","unstructured":"Haveri A, Solastie A, Ekstr\u00f6m N, \u00d6sterlund P, Nohynek H, Nieminen T, et al. Neutralizing antibodies to SARS-CoV-2 omicron variant after third mRNA vaccination in health care workers and elderly subjects. European Journal of Immunology . 2022;0:1\u20139.","DOI":"10.1101\/2021.12.22.21268273"},{"key":"3323_CR78","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMc2113468","volume":"385","author":"AR Falsey","year":"2021","unstructured":"Falsey AR, Frenck RW, Walsh EE, Kitchin N, Absalon J, Gurtman A, et al. SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. N Engl J Med. 2021;385:1627\u20139.","journal-title":"N Engl J Med"},{"key":"3323_CR79","first-page":"677","volume":"0","author":"A Lombardi","year":"2021","unstructured":"Lombardi A, Bozzi G, Ungaro R, Villa S, Castelli V, Mangioni D, et al. Mini review immunological consequences of immunization with COVID-19 mRNA vaccines: preliminary results. Front Immunol. 2021;0:677.","journal-title":"Front Immunol"},{"key":"3323_CR80","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"LA Jackson","year":"2020","unstructured":"Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med. 2020;383:1920\u201331.","journal-title":"N Engl J Med"},{"key":"3323_CR81","doi-asserted-by":"crossref","unstructured":"Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI. Insight. 2019;4.","DOI":"10.1172\/jci.insight.123158"},{"key":"3323_CR82","doi-asserted-by":"crossref","unstructured":"Houser KV, Broadbent AJ, Gretebeck L, Vogel L, Lamirande EW, Sutton T, et al. Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody. PLoS Pathog 2017;13:e1006565.","DOI":"10.1371\/journal.ppat.1006565"},{"key":"3323_CR83","unstructured":"Moderna. Moderna announces longer shelf life for its COVID-19 vaccine candidate at refrigerated temperatures. 2020."},{"key":"3323_CR84","doi-asserted-by":"crossref","unstructured":"Doria-Rose NA, Shen X, Schmidt SD, O\u2019Dell S, McDanal C, Feng W, et al. Booster of mRNA-1273 strengthens SARS-CoV-2 omicron neutralization. medRxiv. 2021.","DOI":"10.1101\/2021.12.15.21267805"},{"key":"3323_CR85","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","volume":"586","author":"N van Doremalen","year":"2020","unstructured":"van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham JN, Port JR, et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020;586:578\u201382.","journal-title":"Nature."},{"key":"3323_CR86","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"PM Folegatti","year":"2020","unstructured":"Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet. 2020;396:467\u201378.","journal-title":"Lancet."},{"key":"3323_CR87","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","volume":"27","author":"KJ Ewer","year":"2021","unstructured":"Ewer KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial. Nat Med. 2021;27:270\u20138.","journal-title":"Nat Med"},{"key":"3323_CR88","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","volume":"396","author":"MN Ramasamy","year":"2020","unstructured":"Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial. Lancet. 2020;396:1979\u201393.","journal-title":"Lancet"},{"key":"3323_CR89","doi-asserted-by":"crossref","unstructured":"Zhang Y, Zeng G, Pan H, Li C, Kan B, Hu Y, et al. Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial. medRxiv. 2020;2020.07.31.20161216-2020.07.31.20161216.","DOI":"10.1101\/2020.07.31.20161216"},{"key":"3323_CR90","doi-asserted-by":"crossref","unstructured":"Canedo-Marroqu\u00edn G, Saavedra F, Andrade CA, Berrios RV, Rodr\u00edguez-Guilarte L, Opazo MC, et al. SARS-CoV-2: immune response elicited by infection and development of vaccines and treatments. Front Immunol 2020;11:569760.","DOI":"10.3389\/fimmu.2020.569760"},{"key":"3323_CR91","doi-asserted-by":"crossref","unstructured":"Bueno SM, Abarca K, Gonz\u00e1lez PA, G\u00e1lvez NMS, Soto JA, Duarte LF, et al. Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial. medRxiv. 2021;2021.03.31.21254494.","DOI":"10.1101\/2021.03.31.21254494"},{"key":"3323_CR92","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","volume":"398","author":"MD Tanriover","year":"2021","unstructured":"Tanriover MD, Do\u011fanay HL, Akova M, G\u00fcner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398:213\u201322.","journal-title":"Lancet."},{"key":"3323_CR93","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S1473-3099(20)30987-7","volume":"21","author":"Z Wu","year":"2021","unstructured":"Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial. Lancet Infect Dis. 2021;21:803\u201312.","journal-title":"Lancet Infect Dis"},{"key":"3323_CR94","doi-asserted-by":"crossref","unstructured":"Sadoff J, le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1\/2a, double-blind, randomized, placebo-controlled trial. medRxiv. 2020;2020.09.23.20199604-2020.09.23.20199604.","DOI":"10.1101\/2020.09.23.20199604"},{"key":"3323_CR95","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff J, le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021;384:1824\u201335.","journal-title":"N Engl J Med"},{"key":"3323_CR96","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","volume":"396","author":"DY Logunov","year":"2020","unstructured":"Logunov DY, Dolzhikova I, , et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia. Lancet. 2020;396:887\u2013897.","journal-title":"Lancet."},{"key":"3323_CR97","unstructured":"Sputnik V. Second interim analysis of clinical trial data showed a 91.4% efficacy for the Sputnik V vaccine on day 28 after the first dose; vaccine efficacy is over 95% 42 days after the first dose. 2020."},{"key":"3323_CR98","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/IDR.S288877","volume":"14","author":"TM Belete","year":"2021","unstructured":"Belete TM. Review on up-to-date status of candidate vaccines for COVID-19 disease. Infect Drug Resist. 2021;14:151\u201361.","journal-title":"Infect Drug Resist"},{"key":"3323_CR99","doi-asserted-by":"publisher","first-page":"7892","DOI":"10.1016\/j.vaccine.2020.10.064","volume":"38","author":"M Guebre-Xabier","year":"2020","unstructured":"Guebre-Xabier M, Patel N, Tian JH, Zhou B, Maciejewski S, Lam K, et al. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine. 2020;38:7892\u20136.","journal-title":"Vaccine."},{"key":"3323_CR100","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","volume":"383","author":"C Keech","year":"2020","unstructured":"Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020;383:2320\u201332.","journal-title":"N Engl J Med"},{"key":"3323_CR101","unstructured":"Nasreen S, Chung H, He S, Brown KA, Gubbay JB, Buchan SA, et al. Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada medRxiv 2021;2021.06.28.21259420."},{"key":"3323_CR102","doi-asserted-by":"crossref","unstructured":"Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. medRxiv. 2021;2021.05.22.21257658.","DOI":"10.1101\/2021.05.22.21257658"},{"key":"3323_CR103","doi-asserted-by":"crossref","unstructured":"Du Z, Wang L, Pandey A, Lim WW, Chinazzi M, Piontti APY, et al. Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India. Nat Med. 2022.","DOI":"10.21203\/rs.3.rs-855843\/v1"},{"key":"3323_CR104","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1002\/jmv.27463","volume":"94","author":"R Rashedi","year":"2022","unstructured":"Rashedi R, Samieefar N, Masoumi N, Mohseni S, Rezaei N. COVID-19 vaccines mix-and-match: the concept, the efficacy and the doubts. J Med Virol. 2022;94:1294\u20139.","journal-title":"J Med Virol"},{"key":"3323_CR105","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(21)01420-3","volume":"398","author":"AM Borobia","year":"2021","unstructured":"Borobia AM, Carcas AJ, P\u00e9rez-Olmeda M, Casta\u00f1o L, Bertran MJ, Garc\u00eda-P\u00e9rez J, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021;398:121\u201330.","journal-title":"Lancet"},{"key":"3323_CR106","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1038\/s41591-021-01464-w","volume":"27","author":"T Schmidt","year":"2021","unstructured":"Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S, et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19\/mRNA vaccination. Nat Med. 2021;27:1530\u20135.","journal-title":"Nat Med"},{"key":"3323_CR107","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3390\/vaccines9080857","volume":"9","author":"L Benning","year":"2021","unstructured":"Benning L, T\u00f6llner M, Hidmark A, Schaier M, Nusshag C, K\u00e4lble F, et al. Heterologous ChAdOx1 nCoV-19\/BNT162b2 prime-boost vaccination induces strong humoral responses among health care workers. Vaccines (Basel). 2021;9:857.","journal-title":"Vaccines (Basel)"},{"key":"3323_CR108","unstructured":"Sesa G, Czabanowska K, Green M, Reid Professor J. Middleton J. The Importance of Health Communication during Emergencies: The Mix-and-Match Question; 2021. p. 1\u201312."},{"key":"3323_CR109","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1126\/science.372.6547.1138","volume":"372","author":"G Vogel","year":"2021","unstructured":"Vogel G. Mixing vaccines may boost immune responses. Science. 2021;372:1138.","journal-title":"Science."},{"key":"3323_CR110","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/d41586-021-01805-2","volume":"595","author":"D Lewis","year":"2021","unstructured":"Lewis D. Mix-and-match COVID vaccines: the case is growing, but questions remain. Nature. 2021;595:344\u20135.","journal-title":"Nature."},{"key":"3323_CR111","doi-asserted-by":"crossref","unstructured":"Hillus D, Schwarz T, Tober-Lau P, Hastor H, Thibeault C, Kasper S, et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1-nCoV19 and BNT162b2: a prospective cohort study. medRxiv. 2021;2021.05.19.21257334.","DOI":"10.1101\/2021.05.19.21257334"},{"key":"3323_CR112","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41591-021-01449-9","volume":"27","author":"J Barros-Martins","year":"2021","unstructured":"Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov M, , et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19\/BNT162b2 vaccination. Nat Med. 2021;27:1525\u20131529.","journal-title":"Nat Med"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-022-03323-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-022-03323-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-022-03323-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,9]],"date-time":"2022-10-09T04:03:20Z","timestamp":1665288200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-022-03323-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":112,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["3323"],"URL":"https:\/\/doi.org\/10.1007\/s11095-022-03323-w","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,1]]},"assertion":[{"value":"5 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}